What Is Step Therapy in Prior Authorization — and How to Navigate It
Step therapy requires patients to try lower-cost drugs before a payer will cover the prescribed medication. Here's how it works, what payers require, and how to document your way through it.
What Is Step Therapy?
Step therapy — sometimes called "fail first" — is a payer policy that requires patients to try one or more less expensive or lower-tier medications before the plan will cover the drug a clinician originally prescribed.
If the first-line drug works, that's the end of it. If it fails — due to inadequate response, side effects, contraindication, or intolerance — the patient "steps up" to the next therapy. Only after working through the required steps will the plan authorize the originally prescribed drug.
Step therapy applies most commonly to specialty and high-cost medications: biologics, brand-name drugs with therapeutic alternatives, and some specialty injectables. It is less common for generic medications.
Why Payers Use Step Therapy
Step therapy is a cost management tool. From the payer's perspective, if a $50/month medication works as well as a $3,000/month medication for most patients, requiring a trial of the cheaper option first reduces plan costs without meaningfully compromising outcomes for the majority of patients.
In practice, clinicians often disagree with where step therapy gets applied. A patient with a history of methotrexate failure years before joining the current plan may still be required to document that failure. A patient for whom the step therapy drug is contraindicated still needs paperwork showing the contraindication. That's where the administrative burden lands.
Common Step Therapy Requirements by Drug Class
Step therapy requirements vary by payer, plan, and indication. These are common patterns — your patient's specific plan may differ:
- ✓ Biologics for RA/PsA: Trial of methotrexate or another conventional DMARD, typically for 3 months at therapeutic dose, before TNF inhibitors or IL-6 inhibitors are covered.
- ✓ Biologics for plaque psoriasis: Trial of topical therapies, phototherapy, and/or methotrexate before IL-17, IL-23, or TNF inhibitors.
- ✓ Biologics for IBD: Adequate trial of corticosteroids and immunomodulators (azathioprine, 6-MP) before anti-TNF or anti-integrin therapies.
- ✓ GLP-1 agonists for type 2 diabetes: Trial of metformin and often a second oral agent before branded GLP-1s are covered.
- ✓ GLP-1 agonists for obesity: Often stricter — some plans require documented trials of multiple lifestyle interventions and other weight loss medications.
- ✓ Specialty ophthalmology drugs: Trial of less expensive anti-VEGF agents before newer or branded alternatives.
How to Document Step Therapy Properly
Proper documentation is what separates an approval from a denial. Vague chart notes are the most common reason step therapy exceptions get rejected.
For each prior therapy your patient tried, document: the drug name and dose, the start date and end date, the reason for discontinuation or inadequate response, and any objective measures of failure (lab values, disease activity scores, flare frequency, side effect severity).
If the prior therapy was tried under a previous provider or insurance plan, get records. Payers can — and do — deny step therapy documentation that lacks specificity, even if the clinical history is clear to you.
When You Can Skip Step Therapy
Most payers allow step therapy exceptions when certain clinical conditions are met. Common grounds for an exception include:
- ✓ Contraindication: The step therapy drug is medically contraindicated for the patient. Document the specific contraindication with clinical evidence.
- ✓ Previous failure: The patient failed the required step therapy drug before enrolling in the current plan. Documentation of the prior failure is required.
- ✓ Clinical urgency: Starting with the lower-tier drug would seriously jeopardize the patient's health. This requires a strong clinical argument and sometimes peer-to-peer review.
- ✓ Drug interaction: The step therapy drug would cause a clinically significant interaction with a medication the patient must continue.
- ✓ Equivalent prior authorization: The patient has active prior authorization for the requested drug from another payer within a qualifying time period.
Check What Your Patient's Payer Requires Before You Prescribe
Step therapy requirements are not consistent across payers. Cigna may require a 3-month methotrexate trial for Humira; UHC may require a different duration or accept a different DMARD. Before you write the prescription and submit the PA, look up what the specific payer requires for that drug and indication.
RxCheckUp shows you the step therapy path for any drug and payer combination — including what documentation you'll need, what qualifies as adequate failure, and whether your patient's history satisfies the requirements — before you submit anything.